ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra"
with headquarters in Berlin and access to a site in Cairo, which will house its principal manufacturing plant. The formation of MiGenTra accelerates ProBioGen's 2030 growth roadmap and showcases that further growth is not limited to the ongoing capacity increase but reveals one of several significant steps in the diversification of ProBioGen's business.
BioGaia has signed an agreement with Minapharm Pharmaceuticals for the exclusive rights to sell BioGaia Protectis drops in Egypt. The probiotic will be sold under the BioGaia brand. Launch is planned to Q4 2021.
Moscow/Cairo/Berlin, April 22, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), Egypt’s Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary ProBioGen AG announce the agreement to produce over 40 million doses per year of the world’s first registered vaccine against COVID-19, Sputnik V.
Minapharm Pharmaceuticals S.A.E has announced today that the German regulatory authority BfArM (Federal Institute for Drugs and Medical Devices) approved a phase 1 clinical trial for its biosimilar teriparatide in Germany. The product has been submitted...
Minapharm announced on July 27th 2020, the appointment of Dr. Shaheer Bardissi and Mr. Tarek Mounib as new members to the board of directors.
Minapharm pharmaceuticals, the leading biopharmaceutical company in Egypt, Africa and the Middle East, announced on June the 1st, the appointment of Dr. Lutz Hilbrich, an experienced biotech executive, as the new CEO of its Berlin-based subsidiary ProBioGen AG.
Minapharm's summer internship for 2018 has concluded successfully after two great months of learning.
The internship was offered from July till to early September ...
As a global leader in biotechnology & cellular engineering, ProBioGen-Minapharm
As a continuation of Minapharm unique series of "Expert Panel",
The meeting was chaired by Prof. Abdel-Shakour EL MOHAMADY.
The First Netilmicin The Least Resistance
The First Netilmicin Combination the Quick Relief for Ocular Inflammation
Striking Glaucoma Treatment Goals Balancing EFFICACY, COMPLIANCE & AFFORADABILITY
Striking Glaucoma Treatment Goals Balancing
EFFICACY, COMPLIANCE & AFFORADABILITY
Stay connected, subscribe to our newsletter for news and updates.